Skip to main content

Table 1 Patient characteristics

From: After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer

  HDR-ISBT+IMRT LDR-ISBT+IMRT p value
n(%) n(%)
Age[years], median(range) 67.8 (54.5-81.4) 65.8 (52.6-78.8) 0.498
Stage    0.867
■T1b 1 (4.5) 1 (6.3)  
■T1c 11 (50) 9 (56.2)  
■T2a 2 (9.1) 1 (6.3)  
■T2b 2 (9.1) 3 (18.8)  
■T2c 2 (9.1) 1 (6.3)  
■T3a 2 (9.1) 1 (6.3)  
■T3b 2 (9.1) 0 (0)  
Initial PSA    0.061
■<10 7 (31.8) 8 (50)  
■ 10-20 8 (36.4) 7 (43.7)  
■>20 7 (31.8) 1 (6.3)  
Gleason Score    0.029*
■<7 0 (0) 0 (0)  
■7 17 (77.3) 16 (100)  
■>7 5 (22.7) 0 (0)  
Risk grouping (NCCN classification)    0.031*
■ Low 0 (0) 0 (0)  
■ Intermediate 12 (54.5) 14 (87.5)  
■ High 10 (45.5) 2 (12.5)  
Baseline t-IPSS, median(range) 8.3 (1.0-23.0) 6.75 (1.5-23.0) 0.982
ADT 10 (45.5) 3 (18.8) 0.087
Folow-up [days], median(range) 1048.5 (409–2199) 1070.5 (617–2199) 0.321
Prostate volume [cc], median(range) 40.8(17.5-94.5) 33.1(13.6-73.8) 0.12
  1. Abbreviations: HDR-ISBT + IMRT combination of HDR-ISBT and intensity-modulated radiation therapy, LDR-ISBT + IMRT combination of LDR-ISBT and intensity-modulated radiation therapy, ADT androgen deprivation therapy, NCCN National Comprehensive Cancer Network